

Astellas Named to FTSE4Good Index Series for the Seventh Consecutive Year

Tokyo, June 28, 2018 - Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has been selected for the seventh consecutive year to be included in the FTSE4Good Index Series, one of the world’s premier indices for socially responsible investment. Out of 14 themes, Astellas received high marks for “Climate Change”, “Labor Standards” and “Corporate Governance”.

Created by the global index provider FTSE Russell¹, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. FTSE Russell uses unique criteria which contain 14 themes relevant to environmental, social and governance practices. The FTSE4Good Index Series is used by a wide variety of market participants to create and assess responsible investment funds and other products.

By fulfilling its corporate social responsibility as a pharmaceutical company, Astellas strives to enhance the sustainability of society and consequently improve its enterprise value.

(1) **FTSE Russell**: a global index leader 100% owned by London Stock Exchange.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at <https://www.astellas.com/en>

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.

Corporate Communications

TEL: +81-3-3244-3201 FAX: +81-3-5201-7473